Company Overview and News

0
Reliance Power Limited - Credit Rating

2018-08-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RPOWER 532939

0
Reliance Power Limited - Credit Rating

2018-08-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RPOWER 532939

0
Tilaiya project: HC seeks govt#39;s stand on releasing Reliance#39;s bank guarantee

2018-07-27 moneycontrol
The Delhi High Court today asked the Centre to explain why it was not releasing the bank guarantee of Reliance Power after it exited the Tilaiya Ultra Mega Power Project (UMPP), saying it was easy to delay a decision when it is someone else's money. "It is very easy to sit on a decision when it is not your money," Justice Vibhu Bakhru told the Centre while giving it three weeks to file an affidavit indicating its stand on Reliance Power Ltd's (RPL) plea for release of its bank guarantee worth about Rs 208 crore.
PFC PWQFY RPOWER 532939 532810

0
Reliance Power net rises 3% to Rs 237.33 cr in Apr-Jun quarter

2018-07-21 moneycontrol
Reliance Power today posted about three percent increase in its consolidated net profit at Rs 237.33 crore in the quarter ended on June 30, 2018. The company had reported a consolidated net profit of Rs 230.85 crore in the quarter ended on June 30, 2017, a BSE filing said.
RPOWER 532939

0
Reliance Power Q1 profit rises 3% to Rs237.33 crore

2018-07-21 livemint
New Delhi: Reliance Power on Saturday posted about 3% increase in its consolidated net profit at ₹237.33 crore in the quarter ended on 30 June 2018. The company had reported a consolidated net profit of ₹230.85 crore in the quarter ended on 30 June 2017, a BSE filing said.
RPOWER 532662 532939 HTMEDIA

0
Reliance Power Limited - Financial Result Updates

2018-07-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RPOWER 532939

0
Reliance Power Limited - Updates

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RPOWER 532939

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...